Login / Signup

Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.

José F VaronaPedro LandeteJose Antonio Lopez-MartinVicente EstradaRoger ParedesPablo Guisado-VascoLucía Fernández de OruetaMiguel TorralbaJesús FortúnRoberto VatesJosé BarberánBonaventura ClotetJulio AncocheaDaniel CarnevaliNoemí CabelloLourdes PorrasPaloma GijónAlfonso MonereoDaniel AbadSonia ZúñigaIsabel SolaJordi RodonNuria Izquierdo-UserosSalvador FudioMaría José PontesBeatriz de RivasPatricia Girón de VelascoBelén SopesénAntonio NietoJavier GómezPablo AvilésRubin LubomirovKris M WhiteRomel RosalesSoner YildizAnn-Kathrin ReuschlLucy G ThorneClare JollyGreg J TowersLorena Zuliani-AlvarezMehdi BouhaddouKirsten ObernierLuis EnjuanesJose M Fernández-Sousanull nullNevan J KroganJosé M JimenoAdolfo García-Sastre
Published in: medRxiv : the preprint server for health sciences (2021)
Plitidepsin, an inhibitor of SARS-Cov-2 in vitro , is safe and positively influences the outcome of patients hospitalized with COVID-19.
Keyphrases
  • sars cov
  • end stage renal disease
  • coronavirus disease
  • newly diagnosed
  • chronic kidney disease
  • ejection fraction
  • respiratory syndrome coronavirus
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes